Norris Perne & French LLP Catalent, Inc. Transaction History

Norris Perne & French LLP

$1.36 Billion
Q3 2024

A detailed history of Norris Perne & French LLP transactions in Catalent, Inc. stock. As of the latest transaction made, Norris Perne & French LLP holds 274,761 shares of CTLT stock, worth $16.2 Million. This represents 1.23% of its overall portfolio holdings.

Number of Shares

274,761

Previous 305,154 9.96%

Holding current value

$16.2 Million

Previous $17.2 Million 3.01%

% of portfolio

1.23%

Previous 1.32%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$56.16 - $60.96 $1.71 Million - $1.85 Million	-30,393 Reduced 9.96%	274,761 $16.6 Million
Q2 2024 Jul 24, 2024	BUY	$53.58 - $57.02 $61,670 - $65,630	1,151 Added 0.38%	305,154 $17.2 Million
Q1 2024 Apr 16, 2024	BUY	$42.56 - $59.82 $595 - $837	14 Added 0.0%	304,003 $17.2 Million
Q4 2023 Jan 22, 2024	SELL	$32.18 - $46.57 $83,153 - $120,336	-2,584 Reduced 0.84%	303,989 $13.7 Million
Q3 2023 Oct 18, 2023	BUY	$44.2 - $50.2 $83,317 - $94,627	1,885 Added 0.62%	306,573 $14 Million
Q2 2023 Jul 19, 2023	BUY	$31.86 - $67.26 $406,310 - $857,766	12,753 Added 4.37%	304,688 $13.2 Million
Q1 2023 Apr 20, 2023	BUY	$45.44 - $74.26 $1.45 Million - $2.37 Million	31,874 Added 12.26%	291,935 $19.2 Million
Q4 2022 Jan 24, 2023	BUY	$41.39 - $81.0 $5.63 Million - $11 Million	135,989 Added 109.6%	260,061 $0
Q3 2022 Oct 13, 2022	BUY	$72.36 - $113.1 $102,317 - $159,923	1,414 Added 1.15%	124,072 $8.98 Million
Q2 2022 Aug 11, 2022	BUY	$87.2 - $114.05 $141,961 - $185,673	1,628 Added 1.35%	122,658 $13.2 Million
Q1 2022 Apr 26, 2022	BUY	$94.19 - $124.49 $204,769 - $270,641	2,174 Added 1.83%	121,030 $13.4 Million
Q4 2021 Jan 26, 2022	SELL	$119.57 - $139.07 $158,310 - $184,128	-1,324 Reduced 1.1%	118,856 $15.2 Million
Q3 2021 Oct 26, 2021	BUY	$109.17 - $142.35 $218,230 - $284,557	1,999 Added 1.69%	120,180 $16 Million
Q2 2021 Jul 20, 2021	SELL	$100.34 - $115.69 $4.38 Million - $5.05 Million	-43,636 Reduced 26.97%	118,181 $12.8 Million
Q1 2021 Apr 30, 2021	SELL	$101.51 - $125.27 $255,196 - $314,928	-2,514 Reduced 1.53%	161,817 $17 Million
Q4 2020 Jan 27, 2021	SELL	$85.88 - $105.36 $3.78 Million - $4.64 Million	-44,022 Reduced 21.13%	164,331 $17.1 Million
Q3 2020 Oct 26, 2020	SELL	$72.74 - $92.5 $3.27 Million - $4.16 Million	-44,969 Reduced 17.75%	208,353 $17.8 Million
Q2 2020 Jul 23, 2020	SELL	$48.02 - $79.04 $172,487 - $283,911	-3,592 Reduced 1.4%	253,322 $18.6 Million
Q1 2020 Apr 16, 2020	BUY	$36.95 - $62.95 $2.16 Million - $3.68 Million	58,456 Added 29.46%	256,914 $13.3 Million
Q4 2019 Jan 22, 2020	BUY	$47.06 - $56.64 $135,909 - $163,576	2,888 Added 1.48%	198,458 $11.2 Million
Q3 2019 Oct 24, 2019	SELL	$47.45 - $58.05 $318,579 - $389,747	-6,714 Reduced 3.32%	195,570 $9.32 Million
Q2 2019 Jul 19, 2019	BUY	$39.26 - $54.21 $1,334 - $1,843	34 Added 0.02%	202,284 $11 Million
Q1 2019 Apr 29, 2019	SELL	$29.84 - $43.92 $109,333 - $160,922	-3,664 Reduced 1.78%	202,250 $8.21 Million
Q4 2018 Jan 28, 2019	SELL	$29.95 - $46.34 $23,301 - $36,052	-778 Reduced 0.38%	205,914 $6.42 Million
Q3 2018 Oct 29, 2018	SELL	$40.12 - $45.55 $41,042 - $46,597	-1,023 Reduced 0.49%	206,692 $9.42 Million
Q2 2018 Jul 24, 2018	SELL	$38.72 - $42.52 $234,681 - $257,713	-6,061 Reduced 2.84%	207,715 $8.7 Million
Q1 2018 Apr 17, 2018	SELL	$39.4 - $47.39 $22,773 - $27,391	-578 Reduced 0.27%	213,776 $8.78 Million
Q4 2017 Jan 23, 2018	SELL	$37.27 - $43.02 $130,109 - $150,182	-3,491 Reduced 1.6%	214,354 $8.81 Million
Q3 2017 Nov 01, 2017	BUY	$33.75 - $41.67 $7.35 Million - $9.08 Million	217,845	217,845 $8.7 Million

Others Institutions Holding CTLT

# of Institutions

513

Shares Held

149M

Call Options Held

575K

Put Options Held

2.03M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.6B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

News

Stay updated on Norris Perne & French LLP with notifications on news.

Account

Norris Perne & French LLP Catalent, Inc. Transaction History